Intraindividual comparison of [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC
Please always quote using this URN: urn:nbn:de:bvb:20-opus-265470
- Purpose The radiolabelled somatostatin analogue [\(^{177}\)Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [\(^{177}\)Lu]Lu-DOTA-TOC. Methods Activity kinetics in organs and tumours after [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC were compared intraindividually in fivePurpose The radiolabelled somatostatin analogue [\(^{177}\)Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [\(^{177}\)Lu]Lu-DOTA-TOC. Methods Activity kinetics in organs and tumours after [\(^{177}\)Lu]Lu-DOTA-EB-TATE and [\(^{177}\)Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy. Resuluts In comparison to [\(^{177}\)Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [\(^{177}\)Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [\(^{177}\)Lu]Lu-DOTA-TOC in 4 of 5 patients. Conclusions Prior to a treatment with [\(^{177}\)Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.…
Author: | Heribert Hänscheid, Philipp E. Hartrampf, Andreas Schirbel, Andreas K. Buck, Constantin Lapa |
---|---|
URN: | urn:nbn:de:bvb:20-opus-265470 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Language: | English |
Parent Title (English): | European Journal of Nuclear Medicine and Molecular Imaging |
ISSN: | 1619-7089 |
Year of Completion: | 2021 |
Volume: | 48 |
Issue: | 8 |
Pagenumber: | 2566-2572 |
Source: | European Journal of Nuclear Medicine and Molecular Imaging 2021, 48(8):2566-2572. DOI: 10.1007/s00259-020-05177-z |
DOI: | https://doi.org/10.1007/s00259-020-05177-z |
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/33452632 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | DOTA-EB-TATE; biokinetics; evans blue; intraindividual comparison; somatostatin receptor |
Release Date: | 2022/09/20 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |